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Background and Aims: Polymorphisms in the immune response genes can contribute
to clearance of hepatitis C virus (HCV) infection but also mediate liver inflammation and
cancer pathogenesis. This study aimed to investigate the association of polymorphisms
in PD-1 (PDCD1), IFNL3 (IL28B), and TLR2 immune related genes in chronic HCV
patients with different hepatic and lymphoproliferative HCV-related diseases.
Methods: Selected PDCD1, IFNL3, and TLR2 genes were tested by molecular
approaches in 450 HCV-positive patients with increasing severity of underlying liver
diseases [including chronic infection (CHC), cirrhosis and hepatocellular carcinoma
(HCC)], in 238 HCV-positive patients with lymphoproliferative diseases [such as
cryoglobulinemia and non-Hodgkin lymphoma (NHL)] and in 94 blood donors (BD).
Results: While the rs12979860 IFNL3 T allele was found a good marker associated with
HCV-outcome together with the rs111200466 TLR2 del variant, the rs10204525 PD-
1.6 A allele was found to have an insignificant role in patients with HCV-related hepatic
disorders. Though in Asian patients the combination of IFNL3 and PD-1.6 markers better
define the HCV-related outcomes, in our series of Caucasian patients the PD-1.6 A-allele
variant was observed very rarely.
Conclusion: Differences in the incidence of HCV-related HCC and clinical response
between Asians and Europeans may be partially due to the distribution of PD-1.6
genotype that we found divergent between these two populations. On the other hand,
we confirmed in this study that the polymorphic variants within IFNL3 and TLR2 immune
response genes are significantly associated with HCV-related disease progression in our
cohort of Italian patients.
Keywords: hepatitis virus C, hepatocellular carcinoma, cirrhosis, lymphoproliferative disorders, gene
polymorphism, PD-1, IFNL3, TLR2
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INTRODUCTION
Hepatocellular carcinoma is the primary malignancy of the liver
that often occurs in the setting of underlying chronic liver
disease, mostly HBV and/or C virus infection (HBV and HCV,
respectively), alcoholic liver disease, and non-alcoholic fatty liver
disease. In the last years the incidence rate of HCC has increased
in the European and American populations (Ryerson et al., 2016),
mostly related to the increase of HCV infection acquired before
the availability of the serologic test.
Curative treatment options for HCC are local resection,
radioembolization and multikinase inhibitors. Available
options in patients with unresectable HCC are liver
transplantation, percutaneous ethanol injection, radiofrequency
ablation, and transcatheter arterial chemoembolization
(Hernaez and El-Serag, 2018).
Unfortunately, most patients have locally advanced or
metastatic HCC at diagnosis and are not eligible for either liver
resection or transplantation. In these cases, despite the attempt to
improve the OS of patients by chemotherapy, radioembolization,
and multikinase inhibitor sorafenib, the OS remains poor
(Llovet et al., 2008). The role of tumor-infiltrating leukocytes
in mediating cancer progression and efficacy of immunotherapy
in other malignancies, like melanoma, are now well recognized.
Thus, although liver represents an “immune privileged” organ,
immunotherapy now quickly evolves as a treatment option for
HCC (Prieto et al., 2015). Based on programmed cell death 1 (PD-
1) and PD-L ligands checkpoint blockade, the immunotherapy
for HCC has shown encouraging results in phase I/II trials of
Nivolumab (Checkmate 040 trial) (El-Khoueiry et al., 2017).
The PD-1/PD-L pathway has been demonstrated to be
engaged in the inhibition of activated T-cells with PD-1 up-
regulated in exhausted CD8 T-cells, a mechanism involved in
hepatic viral persistence. The PD-1 expression has been shown
to associate with the development of HBV-related liver diseases
and the prognosis of HCC patients (Zhang et al., 2010; Li
et al., 2013; Li et al., 2016). A recent proteomic study analyzing
HCC cancer-immune landscape across tumor, non-tumor, and
peripheral blood cells demonstrated the existence of a cancer-
immune gradient which become progressively suppressive from
the non-tumor to the tumor microenvironment (Chew et al.,
2017). Specifically, authors have demonstrated the importance
of the immunosuppressive action caused by exhausted tumor-
infiltrating memory CD8+ T cells expressing high levels of PD-1,
that allows immune evasion by the virus and cancer cells (Blank
et al., 2005; Park et al., 2015). The increase number of exhausted
PD-1+ T-cells was significantly higher in HBV-related vs. non-
viral-associated HCC, and much more increased during the HCC
progression stage (stage 1 vs. stage ≥2) (Chew et al., 2017). PD-
1 was also found significantly up-regulated in CD8+ cytotoxic
Abbreviations: BD, blood donors; 95% CI, 95% confidence interval; CHC, chronic
infection; del, deletion; HBV, chronic hepatitis B; HCC, hepatocellular carcinoma;
HCV, hepatitis C virus; ins, insertion; INFL, interferon lambda; MAF, minor
allele frequency; MC, mixed cryoglobulinemia; NHL, non-Hodgkin lymphoma;
OR, odds ratio; OS, overall survival; PCR, polymerase chain reaction; PD-1,
programmed cell death protein 1; SNP, single nucleotide polymorphisms; TLR, toll
like receptor; UTR, untranslated region.
T-cells in patients with chronic HCV-infection compared to
either HCV-negative subjects or patients with spontaneous HCV
resolution (Golden-Mason et al., 2007). In vitro blockade of PD-
1 has been shown to restore the functional competence of the
HCV-specific T-cells (Golden-Mason et al., 2007).
Two SNP on the chromosome 2 within the PDCD1 gene,
the rs36084323 G/A (PD-1.1) located -606 base pairs upstream
the promoter region at position 242801596 and the rs10204525
G/A (PD-1.6) located at +8669 base pairs in the 3′ UTR at
the position 241850169, have been found to be significantly
associated with the risk to develop HBV-related cirrhosis and
HCC among a Chinese Han population (Zhang et al., 2010; Li
et al., 2013; Peng et al., 2015). The mechanisms underlying this
association are likely due to the rs36084323 G allele, positioned
in a putative binding site for the UCE-2 transcription regulators,
causing the increased expression of PD-1 (Sasaki et al., 2014),
and the rs10204525 A allele, disrupting the binding sequence
for miR-4717 inhibitor within the 3′ UTR of PD-1 mRNA,
which drives increased PD-1 expression (Zhang et al., 2015). In
fact, the miRNA-4717 was demonstrated to affect the luciferase
activity in a dose-dependent manner in cells transfected with a
recombinant vector expressing the luciferase reporter gene under
the transcription control of the PD-1 promoter containing the
rs10204525 G polymorphic variant (Zhang et al., 2015).
Hepatitis C virus leads to chronic hepatitis (CHC) and is
a major cause of liver cirrhosis and HCC. HCV is also a
lymphotropic virus that triggers B-cells and promotes favorable
conditions for B lymphocyte proliferation, including the
autoimmune condition MC and B-cell non-Hodgkin lymphoma
(B-NHL) (De Re et al., 2007; Sansonno et al., 2007).
By exploring the relationship between innate immunity and
HCV-related disorders we found that the IFNL3 C rs12979860
and TLR2 -196-174 ins polymorphisms, both associated with
interferon-treatment response and spontaneous HCV-clearance
as well as with lower HCV viral load, are associated with a
decreased risk of HCV-related diseases and delay the occurrence
of cirrhosis and HCC (De Re et al., 2016).
In the present study, we simultaneously analyzed the
distribution of polymorphic variants in the PD-1, IFNL3,
and TLR2 immune-related genes among Italian patients
affected by HCV-related CHC, cirrhosis and HCC (n = 450)
and we compared the genotype and allele frequencies
with those obtained in patients affected by HCV-related
lymphoproliferative diseases, such as MC and NHL, (n = 238)
and in healthy BD (n = 94).
PATIENTS AND METHODS
Study Design
A total of 148 HCV-infected patients with CHC without cirrhosis
or HCC (48.3% male; median age 57.1 years), 113 patients with
HCV-associated cirrhosis (65.4% males; median age 64.5 years),
189 patients with HCV-associated HCC (73.6% male; median age
68.9 years), 238 HCV-infected patients with lymphoproliferative
disorders (130 MC, 29.1% male, median age 68.0 and 108 NHL,
47.5% male, median age 66.5 years), and 94 healthy BD (89.6%
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TABLE 1 | Clinical characteristics and PD-1.6 genotype of 688 HCV-positive patients and 94 HCV-negative BD.
PD-1.6 A > G (rs10204525)
n Age Male (%) MAF∗ G/G (%) A/G (%) A/A (%) Viral load#◦ HCV genotype◦ (%)
Control subjects
BD 94 42.46 ± 10.1 43 (89.6) 94 0.10 76 (80.9) 18 (19.1) 0 – –
HCV infected patients with liver diseases
CHC 148 57.12 ± 14.1 56 (48.3) 450 0.09 125 (84.5) 20 (13.5) 3 (2.0) 2.32 ± 3.9 51/82 (55.6)
Cirrhosis 113 64.46 ± 11.1 70 (65.4) 0.09 93 (82.3) 19 (16.8) 1 (0.9) 2.71 ± 4.4 15/27 (62.2)
HCC 189 68.86 ± 8.6 103 (73.6) 0.09 154 (81.5) 34 (18.0) 1 (0.5) 1.94 ± 1.9 3/3 (100)
HCV infected patients with lymphoproliferative diseases
MC 130 68.03 ± 9.9 32 (29.1) 238 0.11 103 (79.2) 26 (20.0) 1 (0.8) 3.32 ± 4.4 40/55 (72.7)
NHL 108 66.53 ± 15.1 47 (47.5) 0.10 87 (80.6) 20 (18.5) 1 (0.9) 3.13 ± 4.2 7/11 (63.6)
Total 782 65.9 ± 13.7 351 (44.9) 782 0.10 638 (81.6) 137 (17.5) 7 (0.9) 2.52 ± 3.9 116/178 (65.2)
BD, blood donors; CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; MC, mixed cryoglobulinemia; NHL, non-Hodgkin lymphoma; ±, standard deviation; ∗MAF,
minor allele frequency, corresponding to A allele; #viral load, mean in million; ◦data of viral load and of HCV genotype type 1 were determined in 178 cases.
male; median age 42.5 years) were included in this study. Some
of the individuals recruited for the study are part of a previous
study [18]. Cases added as new are: BD n = 94, CHC n = 76,
cirrhosis = 13, HCC = 102, MC = 130, NHL = 12. Demographic
characteristics of the enrolled patients as well as HCV genotype
and viral load were summarized in Table 1. Patients with CHC
and healthy BD have a lower mean age. Female gender was more
frequent among patients with MC.
The diagnosis of chronic HCV infection was based on
anti-HCV antibodies, elevated ALT serum levels and HCV
RNA positivity for at least 6 months. The diagnosis of
HCC was based on the standard criteria listed in the
European Association for the Study of the Liver (EASL)
that incorporate both invasive and non-invasive measures.
Non-invasive criteria include two imaging techniques, both
demonstrating a focal lesion >2 cm in diameter with features
of arterial hypervascularization. Detection and immunochemical
characterization of cryoglobulins were performed according to
the consensus protocol proposed by the “Associazione Italiana
per la Lotta alle Crioglobulinemie.” The diagnosis of NHL in the
course of HCV infection has been histopathologically confirmed
based on the WHO classification.
The study is in accordance with the principles of the Helsinki
Declaration and all subjects provided written informed consent.
The study was approved by institutional review boards and
independent ethics committees since this was a multicenter
study. Particularly, the study of HCC cases was approved by the
ethical committee EUDRACT (No. 2010-023602-12), Comitato
Etico Indipendente of the Azienda Ospedaliero-Universitaria
“Consorziale Policlinico” di Bari, the scientific board and the
ethics committee of the Istituto Nazionale Tumori “Fond
Pascale”; the institutional review board code SPE 14.084_ AOUC;
comitato Etico Area Vasta Centro AOU Careggi, Firenze.
The HCV antibody test was performed by an enzyme
immunoassay (III-generation EIA) against HCV-core and HCV-
non-structural antigens. The HCV viral load (RNA UI/mL) was
assessed by branched DNA technology (Chiron, Emeryville, CA,
United States) in serum samples of 201 patients at the time
of diagnosis of the HCV-related disorder. HCV genotype was
determined by a commercial, certified, diagnostic test (Versant
HCV Genotype 2.0, Siemens Healthcare Diagnostics, Deerfield,
IL, United States).
Genotyping of PD-1, IFNL3, and TLR2
Polymorphisms
We collected 2 mL of whole blood from each patient and
cryopreserved at −20◦C until use. Total genomic DNA was
extracted from peripheral blood using Qiagen DNAeasy Kit
(QIAGEN, Grand Island, NY, United States). We analyzed
four polymorphisms within the PD.1, IFNL3, and TLR2 genes,
previously described as genetic factors involved in the immune
response and hepatic disease progression (Zhang et al., 2010;
Park et al., 2015; Li et al., 2016; Asian liver center, 2018; CDC,
2018). They include 3 single-nucleotide changes at positions -
606 G/A (rs36084323, PD-1.1) (Xiao et al., 2015) and+8669 G/A
(rs10204525, PD-1.6) within the PD-1 gene (Xiao et al., 2015), at
position+1825 C/T (rs12979860) in the IFNL3 gene (De Re et al.,
2016) and a 22-bp nucleotide del/ins from the position −196 to
−174 (rs111200466) in the untranslated 5′-region of TLR2 gene
(De Re et al., 2016).
Oligonucleotides used for genotyping were listed in
Supplementary Table S1. Particularly, PD-1.1 and PD-1.6
were amplified as described by Zhang et al. (2010) by using
PCR and products subjected to automated bidirectional direct
sequencing analysis (Eurofins Genomics GmbH, Ebersberg,
Germany). Briefly, PCR reactions were performed in 50 µL
reaction mixture containing 30–300 ng of genomic DNA,
10 pmol of each primer, 1.25 Unit of Hot Master Taq DNA
Polymerase (5 Prime GmbH, Hamburg, Germany) and 25 µL
of PreMixJ (MasterAmpTM PCR, Epicentre, Madison, WI,
United States). DNA was amplified in Sure Cycler 8800 thermal
cycler (Agilent Technologies, SantaClara, CA, United States)
starting with an initial denaturation at 94◦C for 3 min, followed
by 30 amplification cycles of denaturation at 94◦C for 30 s,
annealing at 65◦C for 30 s, elongation at 72◦C for 1 and 10 min
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final elongation at 72◦C. PCR amplification generated a fragment
of 730 and 490 bp for the PD-1.1 and PD-1.6, respectively.
IFNL3 genotyping was performed using a specific custom
TaqMan SNP-genotyping Assay (SNP rs12979860; Applied
Biosystem, Foster City, CA, United States) on a 7900HT Fast
Real-Time PCR system (Applied Biosystem, Foster City, CA,
United States) (De Re et al., 2016). Determination of TLR2
polymorphism was performed by allele-specific PCR method.
Fragments of different length (264 and 286 bp), depending on
the presence or absence of the del mutation were visualized
by electrophoresis on a 3.5% agarose gel stained with ethidium
bromide (Supplementary Figure S1). Amplicon sequencing was
used to validate the genotyping techniques.
Statistical Analysis
Specific tests including Fisher’s exact test and one or two-way
analysis of variance were used to compare allele and genotype
frequency of PD-1, TLR2, and IFNL3 polymorphisms between
patient groups with different pathologies and control subjects.
Multivariate logistic regression analysis was performed with
diagnosis as a dependent variable and independent variables,
including age, gender (0 female; 1 male), and each genotype
was also considered. P-value, OR and 95% CIs were calculated.
Genotypes of each polymorphism were assessed according
to dominant (0 wild-type homozygote; 1 heterozygote and
variant homozygote), recessive (0 wild-type homozygote and
heterozygote; 1 variant homozygote) and additive genetic models.
Statistical power calculation was performed by using OSSE
online tool1. Statistical analyses were performed using GraphPad
Prism v6 and SNPStats. P value < 0.05 was considered
statistically significant.
RESULTS
Genotype Frequencies
The genotype and allele frequencies of PD-1.6 in HCV-related
cases and healthy BD are listed in Table 1. Male gender was
predominant in our cohort of BD (89.6%), due to psychological,
cultural, and social reasons. The analysis of PD-1.6 genotype
distributions among HCV-related cases, compared to that of BD
showed no significant association with the risk of development of
liver diseases or lymphoproliferative disorders.
The A-allele MAF PD-1.6 was 0.09 in patients with liver
diseases, 0.10 in patients with lymphoproliferative disorders
and 0.10 in BD. The frequency of PD-1.6 A/A genotype
ranged between 0.5 and 2% in HCV-related cases; 0.8–0.9% in
lymphoproliferative disorders and the allele A, and thus the
genotype A/A, was not found among BD subjects. Differences
in allele frequencies and genotype distribution between HCV-
related diseases and BD were not statistically significant. By
comparing the distribution of PD-1.6 alleles among all HCV-
related liver diseases (CHC, cirrhosis, and HCC) with HCV-
related lymphoproliferative disorders (MC, NHL) a significantly
higher frequency of A allele was found in the latter group (83/817
1http://osse.bii.a-star.edu.sg/calculation2.php
and 50/426, respectively, p = 0.018). However, no statistically
significant difference was observed by comparing the A allele
distribution in HCV-related liver diseases or in HCV-related
lymphoproliferative disorders with that determined in the BD
group. Age and gender of BD did not affect the result of the
study: chi-squared test for trend among individuals with <40;
<50, and ≥50 years old was p = 0.74, 0.22, and 0.62 for PD-
1, IFNL3, and TLR2, respectively; chi-square test for gender
(female vs. male) was p = 0.67, 0.83, and 0.92 and for PD-1,
IFNL3, and TLR2, respectively. The allele frequency and genotype
distribution were also found independent of HCV viral load and
HCV genotype (Table 1).
The PD-1.1 polymorphism was analyzed in 109 HCC cases
and consistently with the allele frequency distribution in the
Caucasian population all samples were found G/G homozygous
for such polymorphism (data not shown).
The analysis of IFNL3 rs12979860 polymorphism was shown
in Table 2. There was an increase of T allele frequency, showing
an additive genotype trend, in patients with liver diseases,
particularly CHC (OR = 1.57; 95% CI, 1.06–2.31), cirrhosis
(OR = 2.10; 95% CI, 1.40–3.16), and HCC (OR = 1.79; 95%
CI, 1.21–2.64) compared to BD controls. This analysis had 78%
power to detect differences in IFNL3 C/T allele distribution.
The frequency of IFNL3 T allele was also higher in patients
with hepatic diseases compared to the lymphoproliferative
diseases (MAF 0.44 vs. 0.36; OR = 1.77, 95%CI 1.40–2.25,
p < 0.0001). In particular, patients with more advanced HCV-
related liver diseases (i.e., cirrhosis and HCC) the frequency of
IFNL3 T/T homozygous genotype was 1.4-fold higher than in MC
and NHL, and 3.3 higher than in BD (Figure 1 and Table 2). The
IFNL3 T/T genotype was also 2.3-fold higher in MC and NHL
patients compared to BD (Figure 1).
The distribution of TLR2 ins/del genotypes is shown in
Table 2. The frequencies of these alleles in the HCV-related
groups did not indicate any significant association, with the
exception of the −196 to −174 del that was significantly
more represented among HCC patients compared to BD
controls (del vs. ins OR = 1.97; 95% CI, 1.17–3.31; p = 0.01).
Moreover, we found a statistically significant difference in
the frequency of del allele in HCV-related patients with MC
lymphoproliferative disease compared to controls (OR = 1.71;
95% CI 1.00–2.91; p = 0.05).
Despite the limited power to detect the effect of TLR2
polymorphism, due to the low MAF, a statistically significant
linear trend has been observed for TLR2 del/del genotype (Chi-
square = 9.94, p = 0.0016) among the HCV-related groups.
Epistatic Interaction Between IFNL3 and
TLR2
The above results indicated that only the polymorphic variations
in IFNL3 and TLR2 genes were associated with susceptibility
to HCV-related diseases in our series (Tables 1, 2). A general
linear regression model was used to identify multiloci genotypes
associated with different HCV-related diseases. For the analysis,
IFNL3-TLR2 genotypes from HCV-related liver and HCV
lymphoproliferative diseases were divided into 4 groups, coded
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TABLE 2 | IFNL3 and TLR2 genotypes among 688 HCV-positive cases and 94 HCV-negative BD.
IFNL3 C > T (rs12979860) TLR-2 ins/del rs111200466)
n C/C (%) C/T (%) T/T (%) MAF∗ OR (95%CI) Ins/Ins (%) Ins/Del (%) Del/Del (%) MAF∗ OR
(95%CI)†
Control subjects
BD 94 42 (44.7) 47 (50.0) 5 (5.3) 0.30 Reference 72 (76.4) 21 (22.3) 1 (1.4) 0.12 Reference
HCV infected patients with liver diseases
CHC 148 44 (29.7) 88 (59.4) 16 (10.8) 0.41 1.57 (1.1–2.3)
p = 0.02
101 (68.2) 41 (27.0) 6 (4.7) 0.16
Cirrhosis 113 26 (23.0) 66 (58.4) 21 (18.6) 0.48 2.10 (1.4–3.2)
p < 0.001
82 (72.6) 26 (23.0) 5 (4.4) 0.16
HCC 144 42 (29.2) 78 (54.2) 24 (16.7) 0.43 1.79 (1.2–2.6)
p = 0.003
97 (67.4) 32 (22.2) 15 (10.4) 0.21 1.97 (1.2–3.3)
p = 0.011
HCV infected patients with lymphoproliferative diseases
MC 130 55 (42.3) 59 (45.4) 16 (12.3) 0.35 86 (66.2) 38 (29.2) 6 (4.6) 0.19 1.71 (1.0–2.9)
p = 0.050
NHL 108 41 (38.0) 54 (50.0) 13 (12.0) 0.37 83 (76.9) 24 (22.2) 1 (0.9) 0.12
Total 737 250 (33.9) 392 (53.2) 95 (12.9) 0.40 521 (70.7) 182 (24.7) 34 (4.6) 0.16
BD, blood donors; CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; MC, mixed cryoglobulinemia; NHL, non-Hodgkin lymphoma; ∗MAF, minor allele frequency,
corresponding to deletion (del) in TLR2 and T-allele in IFNL3; OR, odds ratio; 95% CI, 95% confidence interval; †only significant results have been reported.
as InsC, InsT DelC, DelT and their frequencies were compared to
those obtained in BD and lymphoproliferative vs. liver diseases
(Table 3). Wild-type TLR2-ins- IFNL3-C was the most frequent
group (Table 3). Some multilocus genotypes, i.e., ins-T and del-
T distinguished patients with liver diseases compared to BD
(OR = 1.68; 95% CI 1.06–2.65, p = 0.028) and lymphoproliferative
vs. HCV-related liver disorders [(OR = 0.72; 95% CI 0.56–
0.94), p = 0.014 and (OR = 0.43; 95% CI 0.22–0.85), p = 0.016,
respectively], indicating that these multi loci genes play a
significant role in the development of liver diseases among HCV-
positive subjects.
Comparison of IFNL3 T-allele distribution between groups
of patients affected by different HCV-related liver diseases and
healthy BD underlined the role of such polymorphic variant as
dominant key factor for the progression of cirrhosis to the most
advanced liver diseases in our series (Table 3).
PD-1.6 and IFNL3 MAF Frequencies in
Different Countries
Surveys of HBV infection and the rate of HCC in different
geographic regions showed a great disparity between Asian
and other populations. In fact, the incidence of liver cancer is
about nine-fold higher in Asians compared to white Americans
suggesting that genetic polymorphisms and environmental
risk factors may be responsible for such divergences (Asian
liver center, 2018; CDC, 2018). Therefore, we compared the
frequencies of PD-1.6 and IFNL3 polymorphisms in different
countries reported in the NCBI database2 and the frequencies
found in our series (Table 4). A significant difference in allele
distribution among Asian and Italian population was observed
both for the PD-1.6 (MAF 0.66 vs. 0.10) and IFNL3 (0.08 vs. 0.31)
polymorphisms as shown in Table 4.
2http://www.ncbi.nlm.nih.gov/SNP/
DISCUSSION
Previous studies have demonstrated that elevated expression
of PD-1 in lymphocytes within the liver, especially exhausted
T cells and Tregs, are closely associated with a dysfunction
of the immune response in chronic HBV infection and HBV-
related HCC (Boni et al., 2007; Fisicaro et al., 2010; Hsu et al.,
2010; Wang et al., 2011). Moreover, it has been reported that
PD1.1 and PD-1.6 polymorphisms combined with chronic HBV
infection contribute to the development of HCC in a Chinese
population (Li et al., 2013) and polymorphisms concur in the
development of several tumor types and autoimmune disease
pathogenesis (Momin et al., 2009; Liu et al., 2011; Tahoori et al.,
2011; Li et al., 2013; Tang et al., 2017; Tejeda et al., 2017;
Salmaninejad et al., 2018).
Studies focusing on CHC, by Penna et al. (2007) and
Radziewicz et al. (2007) have shown that up-regulation
of PD-1 affects HCV-specific CD8+ T cell function in
the intrahepatic compartment in patient with chronic HCV
infection. Blockade of the PD-1/PD-L1 interaction was shown
to improve the expansion ability and IFN-γ secretion from
HCV-specific CD8+ T cells (Moreno-Cubero and Larrubia,
2016) and control HCV replication in a chimpanzee model
of CHC, although the efficacy was noted only in those
animals with a critical threshold of pre-existing HCV-specific
CD8+ T cells (Fuller et al., 2013). Additional studies showed
that PD-1 is also critical in the persistence of chronic
viral infections in mice (Barber et al., 2006) and in the
progression of acquired immunodeficiency syndrome in humans
(Day et al., 2006).
In our series we found a slight but not statistically significant
increase of the PD-1.6 A/A genotype in the whole group of
patients with HCV-related disorders compared to the control
group of BD. However, the frequency of PD-1.6 A/A genotype is
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FIGURE 1 | Frequency of IFNL3 genotype distribution among patients stratified on the basis of their HCV-related disease (n = 643) and blood donors (BD) (n = 94).
The frequency of IFNL3 T allele was found increased in HCV-associated liver diseases (CHC, cirrhosis, and HCC) compared to BD and to lymphoproliferative
disorders (MC and NHL). BD, blood donors (controls); CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; MC, mixed cryoglobulinemia; NHL, non-Hodgkin
lymphoma. ∗p < 0.05; ∗∗p < 0.001; and ∗∗∗p < 0.005.
very limited, ranging from 0 to 2% (Table 1) resulting in a allele-A
MAF of 0.10 (Table 4), while this unfavorable A/A genotype
is the most common genotype (52.6%) in Asian population,
with a allele-A MAF of about 0.66 (Table 4; Tang et al., 2017;
Tejeda et al., 2017).
There are remarkable dissimilarities in the distribution of
PD-1.6 polymorphic variants and their association with HCC
between the Asian population and our Italian cohort. Since each
of these studies comprised almost 1000 cases we are incline to
think that differences in the PD-1.6 genotype distribution are
consistent and reflect the genetic heterogeneity among various
populations. On the contrary to Asian population, in our series
we found a very low frequency of PD-1.6 A-allele variant (MAF
0.10, Table 4), thus it is hard to think that this mutation
has a strong role in HCC in our population. Additionally,
it is well known that persistent HBV infection were more
likely to be associated with HCC in Asian population, while
HCV infection had a higher prevalence among the Caucasian
population (Ahmad et al., 2018; Falla et al., 2018). Further studies
are needed to determine the distribution of PD-1.6 variants in
different geographic regions and to explore their casual role in
HCV-related diseases susceptibility worldwide.
Since the PD-1/PD-L1 blockade has proven to be an efficient
treatment for HCC (Kudo, 2016), the lack of parallel changes
in the frequency of PD-1.6 A allele in HCV-related HCC
patients and controls in our series excludes a simple direct
effect of PD-1.6 variant in the pathogenesis of HCC. However,
we cannot exclude the possibility that other polymorphisms in
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TABLE 3 | Comparison of TLR2 and IFNL3 multilocus genotypes frequencies of HCV-related patients with liver (n = 405), HCV-related lymphoproliferative diseases
(n = 238) and blood donors (n = 94).
IFNL3 TLR2 BD CHC Cirrhosis HCC Hepatic
diseases
Hepatic vs. BD
OR (95%CI), p†
BD MC NHL Lympho-proliferative Lympho-proliferative
vs. hepatic
OR (95%CI), p†
C Ins 0.58 0.47 0.45 0.45 0.45 0.58 0.54 0.53 0.53
T Ins 0.29 0.36 0.39 0.35 0.37 1.68 (1.1-2.7)
p = 0.028
0.29 0.30 0.35 0.32 0.72 (0.6–0.9) p = 0.014
C Del 0.10 0.11 0.10 0.13 0.11 0.10 0.12 0.10 0.11
T Del 0.03 0.07 0.07 0.07 0.07 0.03 0.05 0.02 0.04 0.43 (0.2–0.9) p = 0.016
BD, blood donors (controls); CHC, chronic hepatitis C; HCC, hepatocellular carcinoma; MC, mixed cryoglobulinemia; NHL, non-Hodgkin lymphoma; †only significant
results were reported. OR, odds ratio; 95% CI, 95% confidence interval.
TABLE 4 | Distribution of PD-1.6 allele-A and IFNL3 allele-T frequencies in different populations (available in http://www.ncbi.nlm.nih.gov/SNP/ database) and in our
series of HCV-related diseases (n = 710).
MAF Asian Nigerian African American European Italian HCV∗
PD-1.6 A 0.66 0.50 0.39 0.39 0.12 0.10◦ 0.10
IFNL3 T 0.08 0.50 0.67 0.40 0.31 0.31& 0.40
∗Data obtained from our series of patients with a chronic HCV infection (n = 710). ◦data obtained from our series of blood donors (n = 94). &mean data from our series of
HCV-negative patients (n = 94); n = 134 (Taliani et al., 2013); n = 428 (Falleti et al., 2011).
PD-1 or in other immune-related genes, such as the rs12979860
polymorphism in IFNL3 gene, could be involved in HCV-
related diseases in our Italian population (Ge et al., 2009; Riva
et al., 2014; Wack et al., 2015). Alternatively, the discordant
correlation between PD-1.6 and HCV-related HCC susceptibility
across Asian-European populations could be related to an
interaction of the host PD-1.6 gene variant with different
environmental factor(s) present in the two populations or HCC
development could be related to a different immune check
point molecule blockade. Given the important involvement of
PD-1 in autoimmunity and chronic viral infections, further
researches are deserved to clarify the role of PD-1 polymorphism
in these settings.
Genetic polymorphism of IFNL3 was found strongly
associated with spontaneous resolution of HCV infection and
with response to PEGylated interferon-alpha and ribavirin
therapy for chronic HCV (Ge et al., 2009; Tanaka et al., 2009;
Xiao et al., 2015; Huang et al., 2017). The IFNL3 and PD-1
markers in conjunction have also been reported to influence the
susceptibility and outcomes of HCV infection in the Southeast
FIGURE 2 | TLR2/IFN-λ3 protein-protein interaction was performed by using String software. The interleukin 6 (IL6) and INF-α, connecting TLR2 and IFN-λ3, can
turn on the JAK/STAT pathway, the most important pathway in mediating the inflammatory response to HCV via induction of IFN-stimulated genes (ISGs). The final
effect of ISGs results in antigen presentation and a differential expression profile of certain immunomodulatory genes targeting different immune cells and resulting in
the polarization of Th1 and Th2 cells, in the modulation of regulatory T-cells and pro-inflammatory cytokines and in the differentiation of dendritic cells (DCs) from
monocytes (Egli et al., 2014; Douam et al., 2017; Hemann et al., 2017; Syedbasha and Egli, 2017; Zhou et al., 2018).
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China, suggesting their interactions in the disease outcomes
(Xiao et al., 2015). In a previous study we found an association
between TLR2 ins/del and IFNL3 polymorphisms with HCV-
related outcome (De Re et al., 2016). In the present study we
demonstrated that the multilocus TLR2-ins/ IFNL3 T genotype
was a significant factor for development of HCV-related liver
diseases (Table 3), and that the impact of rare PD-1.6 variant
in Italian population is responsible for the discrepancy between
Asian and European results (Table 4). In our series the IFNL3 T
variant was confirming to be one of the best markers associated
with HCV-related pathogenesis, with a marginal role of TLR2
del variant, while in Asian populations the combined IFNL3 and
PD-1.6 polymorphisms were found to better define the HCV-
related outcomes.
Today, we have no data to demonstrate the effect of an
interaction between TLR2 and IFNL3 gene products in HCV-
positive patients, nonetheless, a functional links between these
genes may be indirectly determined using the STRING3 software
based on genomic associations of genes that are required for a
same function. Figure 2 shows the graphical representation of
the model of interaction between TLR2 and IFNL3 leading to
effect of IFNL3 gene expression on the janus kinase (JAK)/signal
transducer and activator of transcription (STAT) (JAK/STAT)
pathway. HCV core and NS3 proteins are known to be able to
trigger inflammatory pathways via TLR2, which may act, along
with TLR1 and TLR6, as a receptor contributing to the activation
of the innate immune system and production of interleukin 6 (IL-
6) and Interferon-alpha (IFN-α) (Dolganiuc et al., 2004; Chang
et al., 2007). In the past before direct-acting antiviral (DAA)
treatment IFN-α therapy was largely demonstrated to reduce the
risk of HCC and complications associated with cirrhosis in HCV
infected individuals and serum IL-6 elevation has been correlated
with liver disease severity, HCV-RNA titer and the activation of
the JAK/STAT pathway (Malaguarnera et al., 1997; Sansone and
Bromberg, 2012; Egli et al., 2014; Kong et al., 2016; Hemann et al.,
2017; Syedbasha and Egli, 2017; Yakut et al., 2018). IFNL3 signal,
producing IFN-λ3 molecules, has been demonstrated to inhibit
HCV infection and induce anti-viral response also through the
JAK-STAT pathway via induction of IFN-stimulated genes (ISGs)
(Malaguarnera et al., 1997; Dolganiuc et al., 2004; Yakut et al.,
2018). IFNL3 induces a cell type specific immune response due
to the cellular expression of IFN-λ3s receptors in fewer cell types
(Egli et al., 2014) and activates the JAK-STAT pathway by a
feed-forward fashion with substantial differences in terms of the
ISGs gene expression induced by IFN-α. Indeed, IFN-λ3 showed
many antiviral properties but with an overall smaller response
than IFN-α causes (Hemann et al., 2017; Syedbasha and Egli,
2017; Zhou et al., 2018). The IFN-λ3 effect is mainly associated
with antigen presentation and a differential expression profile
of certain immunomodulatory genes compared to IFN-α and
this suggests a specific functional role for IFN-λ3. A critical role
of IFN-λ3n in the polarization of Th1 and Th2 cells, in the
modulation of regulatory T-cells and pro-inflammatory cytokines
and in the differentiation of dendritic cells (DCs) have been
3 https://string-db.org/cgi/input.pl?sessionId=7AG0SO9%20cCRu4&input%20_
page_show_search=on
well described in several reviews (Egli et al., 2014; Douam et al.,
2017; Hemann et al., 2017; Syedbasha and Egli, 2017; Zhou
et al., 2018). Of note, during infection with HCV, the expression
pattern of many of the ISGs significantly change, most likely
due to immunomodulatory effects of HCV proteins and complex
inhibitory effects of IFN signaling pathways (Thomas et al., 2012;
Egli et al., 2014). In particular, the long-term effects on the
Th1/Th2 balance might have implications for the priming of T-
and B-cell dependent memory responses, and thus possibly on
HCV-related lymphoproliferative malignancy and autoimmune
disease prevalence (Egli et al., 2014).
Thus, an indirect interaction between IFNL3 and TLR2 gene
products may be suggested from data of literature, but further
studies are necessary to confirm the effect of IFNL3 and TLR2
polymorphisms in the prediction of the above reported functional
signaling in HCV patients.
This is the first study evaluating the PD1 polymorphisms
and the risk of HCV-related disorders in the Italian population.
The results should be regarded as descriptive observations and
larger studies with more diverse ethnic populations are needed to
confirm the association of immune related gene polymorphisms
in HCV-related diseases.
In conclusion our study highlighted the importance of
geographical difference in the frequencies of PD-1 and IFNL3
genetic polymorphisms in HCV-related diseases particularly in
cirrhosis and in HCC susceptibility. Due to the importance
of these genes in the immune response to hepatic infection,
autoimmune disorders and malignancies as well as their
role in the response to new proposed immune check-point
treatment for HCC, further studies are needed to better
understand the pathogenic role of these genetic variants in HCV-
related diseases.
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